The salvage therapy utilizing human umbilical cord-derived mesenchymal stem cells for the treatment of critically ill patients with COVID-19.

ABSTRACT:

Background

The therapeutic options for patients with coronavirus disease (COVID-19) are limited. Mesenchymal stem cells (MSCs) have immunomodulatory and regenerative properties that may inhibit excessive inflammatory responses, promote recovery from COVID-19-induced lung injury, and potentially serve as a therapeutic option.

Methods

An evaluation of the safety and efficacy of using human umbilical cord mesenchymal stem cells (hUC-MSCs) in 5 critically ill patients with COVID-19 was conducted in this study. In all patients, hUC-MSCs were administered intravenously three times at a dosage of 3 × 10⁷ cells per time, 2 days between each infusion. Safety was evaluated using adverse events. The efficacy was assessed by coagulation function (serum D dimer), inflammatory

SUBMITTER: Yao W 

PROVIDER: S-EPMC12271227 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature